Test Bank For Pharmacotherapeutics for Advanced Practice 3rd Edition by Virginia Poole Arcangelo, Andrew M. Peterson
Original price was: $75.00.$35.00Current price is: $35.00.
Test Bank For Pharmacotherapeutics For Advanced Practice 3rd Edition By Virginia Poole Arcangelo, Andrew M. Peterson is a comprehensive guide that provides an overview of pharmacotherapy principles and their application to common clinical scenarios encountered by advanced practice providers. The text includes detailed discussion of the pathophysiology of disease states and the pharmacologic principles underlying the selection and management of drugs used to treat these conditions.
Test Bank For Pharmacotherapeutics For Advanced Practice 3rd Edition By Virginia Poole Arcangelo, Andrew M. Peterson also includes coverage of key topics such as drug interactions, adverse effects, and prescribing for special populations. Case studies are included throughout to help readers apply concepts to real-world situations. Test Bank For Pharmacotherapeutics For Advanced Practice 3rd Edition By Virginia Poole Arcangelo, Andrew M. Peterson is an essential resource for anyone preparing for a career in advanced practice pharmacotherapy.
Digital item No Waiting Time Instant Download
ISBN-10: 1451111975 ISBN-13: 9781451111972
Description
Test Bank For Pharmacotherapeutics for Advanced Practice 3rd Edition by Virginia Poole Arcangelo, Andrew M. Peterson
Chapter 3. Impact of Drug Interactions and Adverse Events on Therapeutics
MULTIPLE CHOICE
1. Which of the following patients would be at higher risk of experiencing adverse drug reactions (ADRs):
A.
A 32-year-old male
B.
A 22-year-old female
C.
A 3-month-old female
D.
A 48-year-old male
ANS: C PTS: 1
2. Infants and young children are at higher risk of ADRs due to:
A.
Immature renal function in school-age children
B.
Lack of safety and efficacy studies in the pediatric population
C.
Children’s skin being thicker than adults, requiring higher dosages of topical medication
D.
Infant boys having a higher proportion of muscle mass, leading to a higher volume of distribution
ANS: B PTS: 1
3. The elderly are at high risk of ADRs due to:
A.
Having greater muscle mass than younger adults, leading to higher volume of distribution
B.
The extensive studies that have been conducted on drug safety in this age group
C.
The blood-brain barrier being less permeable, requiring higher doses to achieve therapeutic effect
D.
Age-related decrease in renal function
ANS: D PTS: 1
4. The type of adverse drug reaction that is the result of an unwanted but otherwise normal pharmacological action of a drug given in the usual therapeutic doses is
A.
Type A
B.
Type B
C.
Type C
D.
Type D
ANS: A PTS: 1
5. Digoxin may cause a Type A adverse drug reaction due to:
A.
Idiosyncratic effects
B.
Its narrow therapeutic index
C.
Being a teratogen
D.
Being a carcinogen
ANS: B PTS: 1
6. Changes in the individual pharmacokinetic parameters of adsorption, distribution, or elimination may result in high concentrations of the drug in the body, leading to which type of adverse drug reaction?
A.
Type A
B.
Type C
C.
Type D
D.
Type E
ANS: A PTS: 1
7. According to the World Health Organization Classification, Type B adverse reactions are:
A.
When a drug is a teratogen
B.
When a drug is carcinogenic
C.
A delayed ADR, such as renal failure
D.
An allergic or idiosyncratic response
ANS: D PTS: 1
8. Sarah developed a rash after using a topical medication. This is a Type __ allergic drug reaction.
A.
I
B.
II
C.
III
D.
IV
ANS: D PTS: 1
9. A patient may develop neutropenia from using topical Silvadene for burns. Neutropenia is a(n):
A.
Cytotoxic hypersensitivity reaction
B.
Immune complex hypersensitivity
C.
Immediate hypersensitivity reaction
D.
Delayed hypersensitivity reaction
ANS: A PTS: 1
10. Anaphylactic shock is a:
A.
Type I reaction, called immediate hypersensitivity reaction
B.
Type II reaction, called cytotoxic hypersensitivity reaction
C.
Type III allergic reaction, called immune complex hypersensitivity
D.
Type IV allergic reaction, called delayed hypersensitivity reaction
ANS: A PTS: 1
11. James has hypothalamic-pituitary-adrenal axis suppression from chronic prednisone (a corticosteroid) use. He is at risk for what type of adverse drug reaction?
A.
Type B
B.
Type C
C.
Type E
D.
Type F
ANS: B PTS: 1
12. The treatment for a patient who experiences hypothalamic-pituitary-adrenal axis suppression while taking the corticosteroid prednisone, a Type C adverse drug reaction, is to:
A.
Immediately discontinue the prednisone
B.
Administer epinephrine
C.
Slowly taper the patient off of the prednisone
D.
Monitor for long-term effects, such as cancer
ANS: C PTS: 1
13. The ACE inhibitor lisinopril is a known teratogen. Teratogens cause Type ____ adverse drug reaction.
A.
A
B.
B
C.
C
D.
D
ANS: D PTS: 1
14. Cardiac defects are a known Type D adverse drug reaction to lithium. Lithium causes a Type D adverse drug reaction because it is:
A.
An immunosuppressant
B.
A carcinogen
C.
A teratogen
D.
An antiseizure medication
ANS: C PTS: 1
15. Immunomodulators such as azathioprine may cause a delayed adverse drug reaction known as a Type D reaction because they are known:
A.
Teratogens
B.
Carcinogens
C.
To cause hypersensitivity reactions
D.
Hypothalamus-pituitary-adrenal (HPA) axis suppressants
ANS: B PTS: 1
16. A 24-year-old male received multiple fractures in a motor vehicle accident that required significant amounts of opioid medication to treat his pain. He is at risk for Type __ adverse drug reaction when he no longer requires the opioids.
A.
A
B.
C
C.
E
D.
G
ANS: C PTS: 1
17. Drugs that may cause a Type E adverse drug reaction include:
A.
Beta blockers
B.
Immunomodulators
C.
Antibiotics
D.
Oral contraceptives
ANS: A PTS: 1
18. Unexpected failure of drug therapy is a Type __ adverse drug reaction, commonly caused by____.
A.
B; cytotoxic hypersensitivity
B.
B; idiosyncratic response
C.
C; cumulative effects of drug
D.
F; drug-drug interaction
ANS: D PTS: 1
19. Clopidogrel treatment failure may occur when it is co-administered with omeprazole, known as a Type __ adverse drug reaction.
A.
A
B.
C
C.
E
D.
F
ANS: D PTS: 1
Be the first to review “Test Bank For Pharmacotherapeutics for Advanced Practice 3rd Edition by Virginia Poole Arcangelo, Andrew M. Peterson”